David Phizackerley

Deputy Editor at Drug and Therapeutics Bulletin

Host at DTB podcast

Featured in: Favicon

bmj.com (+1)

Articles

Inappropriate 'prescribing'

2 weeks ago | bmj.com | David Phizackerley

Dear EditorI am a keen parkrunner and thoroughly enjoy the sense of community and camaraderie created by all the local enthusiasts who volunteer and encourage sprinters, runners, trotters and walkers to complete the 5k course each week. There is a great sense of satisfaction in taking part as a runner or as a volunteer - there are not many places where you can stand wearing a crimson hi-vis gilet directing people where to go and get thanked for your efforts several hundred times.
Paying the price

1 month ago | dtb.bmj.com | David Phizackerley |BMJ Journals

Drug-Related Side Effects and Adverse Reactions Health Care Quality, Access, and Evaluation In January 2025, an article published in The Lancet assessed the population-health impact of medicines that had been approved by the National Institute for Health and Care Excellence (NICE) between 2000 and 2020.1 Huseyin Naci and colleagues calculated a net health benefit from each new medicine and the estimated effect that theoretically could be obtained by using the money spent on those medicines...
Prioritising shared decision-making

2 months ago | dtb.bmj.com | Michael Wilcock |David Phizackerley |BMJ Journals

Drug-Related Side Effects and Adverse ReactionsHealth Care Quality, Access, and EvaluationThe importance of patient-centred care and the active engagement and involvement of patients in decisions about their own healthcare have long been recognised.1 For some treatment decisions, the best option may be obvious, but for many others, especially for preventative treatments, there can be several choices open to the patient.
Supporting the treatment of obesity

Sep 6, 2024 | dtb.bmj.com | David Phizackerley |BMJ Journals

Supporting the treatment of obesity Statistics from Altmetric.com Request Permissions If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Finasteride 5mg: are 7-day prescriptions supplied for male pattern hair loss or for compliance aids?

May 10, 2024 | bmj.com | David Phizackerley

Dear EditorIn his reply to the item about the MHRA's warning on finasteride adverse effects, Peter Selley reports that 70,000 prescriptions for seven tablets of finasteride 5mg are dispensed across NHS England each month. He speculates that this may represent considerable use of NHS resources for male pattern hair loss if patients are receiving an NHS prescription for 5mg tablets and then splitting each tablet into four parts.
Protecting consumers: a rich legacy

Feb 12, 2024 | dtb.bmj.com | David Phizackerley |BMJ Journals

Health Care Quality, Access, and EvaluationDrug-Related Side Effects and Adverse ReactionsThe history of drug bulletins is closely linked with the consumer movement of the late 1950s and early 1960s.
Re: Sidney Wolfe: public health leader who campaigned for reform across the US health system

Feb 12, 2024 | bmj.com | David Phizackerley

Dear EditorAll of us at Drug and Therapeutics Bulletin (DTB) are deeply saddened by news of the death of our friend and colleague Sid Wolfe. We have many happy memories of meeting Sid at events run by the International Society of Drug Bulletins (ISDB) at which he would speak eloquently and passionately about problems associated with the regulation of medicines and the need to challenge decisions made by organisations such as the US Food and Drug Administration and the European Medicines Agency.
Semaglutide reduces the absolute risk of major cardiovascular events by 1.5%

Jan 14, 2024 | bmj.com | David Phizackerley

David Phizackerley, deputy editorDrug and Therapeutics Bulletin, London, UKdphizackerley{at}bmj.comThe BMJ reports the results of a recently published clinical trial of semaglutide in 17 604 people aged 45 or over with cardiovascular disease (but not diabetes) and a BMI ≥27.12 The study provides some welcome evidence on the effect of semaglutide on clinically important cardiovascular events and on adverse events leading to withdrawal from treatment.
Molnupiravir: evidence by press release

Dec 4, 2023 | dtb.bmj.com | James Cave |David Phizackerley |BMJ Journals

drug-related side effects and adverse reactionshealthcare qualityaccessand evaluationOn 4 November 2021, the Medicines and Healthcare products Regulatory Agency (MHRA) announced that it had approved molnupiravir (▼Lagevrio) as the first oral antiviral drug authorised for COVID-19.1 In its press release, the MHRA chief executive was quoted as saying, “Lagevrio is another therapeutic to add to our armoury against COVID-19.
Semaglutide reduces the absolute risk of major cardiovascular events by 1.5%

Nov 17, 2023 | bmj.com | David Phizackerley

Dear EditorJacqui Wise (BMJ 2023;383:p2668) provides a prompt and helpful overview of the recently published study on the effect of semaglutide on cardiovascular outcomes in people aged ≥45 years with cardiovascular disease (but not diabetes) and a BMI ≥27 kg/m2. The study provides some welcome evidence on the effect of semaglutide on clinically important cardiovascular events and on adverse events leading to withdrawal from treatment.